Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGES | O14684 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515506 | 0.90 | RAB9A (0.62) | RAB9APOLBNPC1SMN1; SMN2LMNA | |
| SCHEMBL6857070 | 0.80 | POLB (0.74) | RAB9APOLBSMN1; SMN2MAPTKDM4E | |
| SCHEMBL6797484 | 0.79 | POLB (0.72) | RAB9APOLBSMN1; SMN2LMNAGAA | |
| SCHEMBL10920778 | 0.78 | POLB (1.00) | RAB9APOLBSMN1; SMN2LMNAGAA | |
| SCHEMBL6855545 | 0.73 | TP53 (0.57) | RAB9ANPC1SMN1; SMN2LMNAGAA | |
| SCHEMBL4729244 | 0.73 | NPSR1 (0.76) | POLBNPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL6856148 | 0.72 | PLK1 (0.52) | RAB9ANPC1SMN1; SMN2LMNAGAA | |
| SCHEMBL6791736 | 0.72 | TP53 (0.60) | RAB9ANPC1SMN1; SMN2LMNAGAA | |
| SCHEMBL1031735 | 0.71 | TSHR (0.53) | RAB9ANPC1SMN1; SMN2LMNAGAA | |
| SCHEMBL6856455 | 0.71 | TP53 (0.57) | RAB9ANPC1SMN1; SMN2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | disclosed |
| EP-1419159-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO 4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | disclosed |
| WO-2003016314-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO[4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | PDE3A, PDE4A, PDE5A | RAB9A 2106/4885POLB 739/4885NPC1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.